-
Tirzepatide- Tirzepatide has emerged as a promising option for treating obesity. In clinical trials, tirzepatide has been shown to result in significant weight loss compared to a placebo while also improving key metabolic markers such as blood pressure, lipid profiles, and insulin resistance. Moreover, GLP1 has been associated with a lower risk of cardiovascular events in individuals with obesity, highlighting potential advantages beyond weight reduction. This medication presents a valuable new alternative for people struggling with obesity, particularly for those who have not found success through lifestyle changes alone.Included is 1 vial which lasts 8-9 weeks depending on dose, needles and supplies, and overnight refrigerated shipping Â
Proudly serving all 50 statesÂ
*Only available if prescribed after an online consultation with a healthcare provider. Semaglutide and Tirzepatidelans are offered as a subscription service which require a 4 month commitment. *Actual product packaging may appear differently than shown. Physicians may prescribe compounded medications as needed to meet patient requirements or drug shortages. Physicians may alter quantity and dosing with your knowledge prior to ordering from pharmacy. *The FDA does not review or approve any compounded medications for safety or effectiveness. *Has not been approved by the FDA for these uses but studies have shown benefits. Results may vary.